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Humans outgrow their need for a TLR-activated 
kinase, according to a new study by Ku et al. (page 
2407). The kinase helps protect young children from 
specific pathogens but is expendable in adults.
The TLRs are part of an early infection warning 
system that recognizes microbial intrusion. Many 
activated TLRs recruit a kinase called IRAK-4, 
which switches on immune-boosting transcription 
pathways.
In mice, IRAK-4 is thought to be a crucial cog 
in innate defense, as mice of all ages lacking the 
kinase are vulnerable to many different viruses, 
bacteria, and fungi. But the human version now 
appears to be less comprehensive.
The new study examined 28 patients with 
IRAK-4 mutations. Immune cells from these patients’ 
blood failed to produce inflammatory cytokines in 
response to TLR ligation. During infancy and child-
hood, these patients experienced repeated, sometimes 
lethal infections mainly with Streptococcus pneumoniae 
and Staphylococcus aureus. Resistance to other patho-
gens might stem from TLRs that bypass IRAK-4, 
including possibly TLR3 
and TLR4, or from non-
TLR pathways.
About half of the young 
children succumbed to 
the bacterial infections. 
But the patients’ resistance 
improved with age, and 
older children consistently 
survived infections. The 
impact of IRAK-4 defi-
ciency might fade as the 
adaptive immune network, 
particularly memory responses by T and B cells, 
kicks in later in life.
It is unclear why IRAK-4 deficiency preferen-
tially opens the door for some invasive bacteria but 
not other pathogens. The team has previously 
identified defects in other innate immunity factors 
that render patients susceptible to just one patho-
gen. A mechanistic explanation for this selectivity 
is yet to be found. 
Human dendritic cells that lack IRAK-4 (gray bars) 
do not produce inflammatory cytokines in 
response to most TLR signals.
Improving survival after sepsis
The only drug that can save patients from severe sepsis carries a risk of 
internal bleeding. Kerschen et al. (page 2439) have now engineered a variant 
version that offers the same benefits as the original but minimizes the risk.
Sepsis is a system-wide inflammation that occurs when an infecting 
microbe enters the bloodstream. The inflammation is meant to fight the 
pathogen, but it also triggers widespread clotting. Clotting proteins, in 
turn, reinforce inflammation by activating oxidants and proteases, 
ultimately causing organ failure. Because the exact cause of death in 
sepsis patients is unknown, scientists don’t know what problem to target 
when designing an effective therapy.
Antiinflammatory agents such as steroids and cytokine antagonists 
have failed as therapies. So too have anticlotting agents. The only 
treatment that has had any degree of success is activated protein C (APC).
APC is both a clot-busting enzyme and a signaling molecule that blocks apoptosis, inflammatory 
cytokine production, and immune cell recruitment. APC is therefore thought to work against sepsis 
by breaking the inflammation/clotting cycle. But patients dosed with APC can experience internal 
bleeding thanks to the drug’s anticlotting activity.
Kerschen and colleagues now test whether APC might still be effective but less dangerous if its 
anticlotting activity is reduced. They engineered an APC variant that was 90% less effective at stopping 
clotting. This variant was just as good as normal APC at saving septic mice, suggesting that the 
protective effect of APC did not stem from its anticlotting function but from its signaling ability.
Exactly why APC’s antiinflammatory signaling activity succeeds in treating sepsis where other 
antiinflammatory drugs have failed is unclear, but this might be due to its broader effects on both the 
inflammatory and apoptotic pathways. 
Outgrowing IRAK-4
Mice are protected from sepsis-induced death by an 
APC variant that lacks its anticlotting activity (circle).